Aug 16, 2021 5:30pm EDT Medexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022
Aug 12, 2021 7:30am EDT Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients
Aug 10, 2021 1:00pm EDT Medexus Pharmaceuticals to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021
Aug 04, 2021 10:58am EDT Medexus Schedules Webinar to Discuss FDA Complete Response Letter for Treosulfan
Jul 12, 2021 9:29am EDT Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
